Human BCR _ABL (P465S) BAF3 Cell Line

Description

The BCR ABL (P465S) BAF3 Cell Line is established by stable lentiviral expression of the BCR-ABL fusion gene with a P465S mutation in the ABL kinase domain. This point mutation alters the activation loop, affecting inhibitor binding. Expression is validated by qRT-PCR.
Target
The BCR-ABL P465S mutation contributes to kinase hyperactivation and resistance to certain TKIs. It plays a critical role in advanced CML progression and relapse. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.